Ahmad Awada

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. ncbi Will the dark sky over advanced renal cell carcinoma soon become brighter?
    V D'Hondt
    Clinic of Medical Oncology, Institut Jules Bordet, Bd de Waterloo 125, Brussels 1000, Belgium
    Eur J Cancer 41:1246-53. 2005
  2. doi Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene
    Ahmad Awada
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Electronic address
    Clin Breast Cancer 16:364-371. 2016
  3. pmc Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Boulevard de Waterloo 121, B 1000, Brussels, Belgium
    Invest New Drugs 33:611-20. 2015
  4. doi Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
    Ahmad Awada
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Electronic address
    Lancet Oncol 14:1216-25. 2013
  5. pmc Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
    Andrea Gombos
    Medical Oncology Clinic, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Invest New Drugs 30:2433-42. 2012
  6. doi Targeted therapies of solid cancers: new options, new challenges
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 25:296-304. 2013
  7. pmc Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
    A H Awada
    Institut Jules Bordet Brussels, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, Brussels, Belgium
    Invest New Drugs 31:734-41. 2013
  8. doi Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
    A Awada
    Medical Oncology Clinic, Jules Bordet Institute, Brussels University, Brussels
    Ann Oncol 24:109-16. 2013
  9. doi New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
    Ahmad Awada
    Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 38:494-504. 2012
  10. doi Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet Université Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 24:297-304. 2012

Detail Information

Publications116 found, 100 shown here

  1. ncbi Will the dark sky over advanced renal cell carcinoma soon become brighter?
    V D'Hondt
    Clinic of Medical Oncology, Institut Jules Bordet, Bd de Waterloo 125, Brussels 1000, Belgium
    Eur J Cancer 41:1246-53. 2005
    ..Several agents that target known biological abnormalities of the disease are now being tested in the clinic. This review describes the encouraging clinical results obtained to date with these new drugs or combinations of drugs...
  2. doi Phase 2 Study of Trabectedin in Patients With Hormone Receptor-Positive, HER-2-Negative, Advanced Breast Carcinoma According to Expression of Xeroderma Pigmentosum G Gene
    Ahmad Awada
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Electronic address
    Clin Breast Cancer 16:364-371. 2016
    ....
  3. pmc Phase I trial of volasertib, a Polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Boulevard de Waterloo 121, B 1000, Brussels, Belgium
    Invest New Drugs 33:611-20. 2015
    ..6)...
  4. doi Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomised phase 2 study
    Ahmad Awada
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium Electronic address
    Lancet Oncol 14:1216-25. 2013
    ..We aimed to assess the efficacy and safety of two etirinotecan pegol dosing schedules in patients with previously treated metastatic breast cancer to determine an optimum dosing schedule for phase 3 trials...
  5. pmc Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
    Andrea Gombos
    Medical Oncology Clinic, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Invest New Drugs 30:2433-42. 2012
    ..We also tried to extract based on clinical and translational data some candidate biomarkers that could help better to select patient population who potentially could benefit most from this therapeutic approach...
  6. doi Targeted therapies of solid cancers: new options, new challenges
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 25:296-304. 2013
    ..This shift in therapies raises multiple challenges including the appearance of new toxicities, the need for biomarkers, the emergence of genomics and the evolution of cancer molecular imaging...
  7. pmc Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors
    A H Awada
    Institut Jules Bordet Brussels, Universite Libre de Bruxelles, 121 Boulevard de Waterloo, Brussels, Belgium
    Invest New Drugs 31:734-41. 2013
    ..A phase I study to assess the maximum tolerated dose (MTD) of a short course of afatinib in combination with docetaxel for the treatment of solid tumors...
  8. doi Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
    A Awada
    Medical Oncology Clinic, Jules Bordet Institute, Brussels University, Brussels
    Ann Oncol 24:109-16. 2013
    ..Neratinib (HKI-272) is a potent irreversible pan-ErbB tyrosine kinase inhibitor with clinical activity in patients with ErbB2/HER2-positive breast cancer...
  9. doi New therapies in HER2-positive breast cancer: a major step towards a cure of the disease?
    Ahmad Awada
    Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 38:494-504. 2012
    ..Innovative clinical studies are required in well-characterized patient populations to define the true clinical value of these emerging new approaches...
  10. doi Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet Université Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 24:297-304. 2012
    ..This review will detail some of the recent findings that led to better subtyping and treatment of cancers, some of which were historically refractory...
  11. doi Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours
    Ahmad Awada
    Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Eur J Cancer 48:465-74. 2012
    ..The safety, pharmacokinetics and efficacy of sorafenib plus docetaxel in patients with advanced refractory cancer were investigated in a phase I, dose-escalation trial...
  12. pmc The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma
    Laetitia Gerlier
    Health Economics and Outcomes Research Department, IMS Health Consulting, Medialaan 38, 1800 Vilvoorde, Belgium
    BMC Cancer 10:642. 2010
    ..The existence of a medical need for G-CSF primary and secondary prophylaxis with these regimens was investigated in a real-life setting...
  13. ncbi An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes
    A Awada
    Jules Bordet Institute, Chemotherapy Unit, Bd de Waterloo 125, 1000 Brussels, Belgium
    Eur J Cancer 38:773-8. 2002
    ....
  14. ncbi Clinical phase I and pharmacokinetic study of S 16020, a new olivacine derivative: report on three infusion schedules
    A Awada
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 13:1925-34. 2002
    ..Based on the overall data of the three infusion schedules of S 16020, the dose of 100 mg/m(2) over 3 h every 3 weeks was selected for phase II studies...
  15. ncbi An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours
    A Awada
    Jules Bordet Institute, Brussels, Belgium
    Eur J Cancer 39:742-7. 2003
    ..Prolongation of the treatment interval to 6 weeks, based upon the long half-life of the drug in the plasma and tissue, observed during this study, seemed not to be feasible in this heavily pretreated group of patients...
  16. ncbi The pipeline of new anticancer agents for breast cancer treatment in 2003
    A Awada
    Jules Bordet Institute, Chemotherapy Unit, Boulevard de Waterloo 125, 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 48:45-63. 2003
    ..This review will focus on new agents, cytotoxic, hormonal and molecular-targeted, which are in advanced clinical stages of development for the treatment of MBC...
  17. ncbi New anticancer agents and therapeutic strategies in development for solid cancers: a clinical perspective
    Ahmad Awada
    Chemotherapy Unit, Jules Bordet Institute, Rue Heger Bordet, 1, B 1000 Brussels, Belgium
    Expert Rev Anticancer Ther 4:53-60. 2004
    ..A clinical perspective of these agents as monotherapy or combination therapy will be presented in this paper...
  18. ncbi Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers
    A Awada
    Jules Bordet Institute, Brussels, Belgium
    Anticancer Drugs 15:499-502. 2004
    ..This schedule of temozolomide allowed higher dose intensity (1750 mg/m in 4 weeks) compared to the standard 5-day regimen (1000 mg/m in the same amount of time)...
  19. pmc Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
    A Awada
    Jules Bordet Institute, Brussels, Belgium
    Br J Cancer 92:1855-61. 2005
    ..BAY 43-9006 given for 21 days with 7 days off treatment was safe, well tolerated, and showed antitumour activity...
  20. ncbi A phase I clinical and pharmacokinetic study of tipifarnib in combination with docetaxel in patients with advanced solid malignancies
    Ahmad Awada
    Jules Bordet Institute, Brussels, Belgium
    Curr Med Res Opin 23:991-1003. 2007
    ..This phase I study assessed the maximum tolerated doses (MTDs), safety, pharmacokinetics, and efficacy of combined tipifarnib and docetaxel treatment in patients with advanced solid malignancies...
  21. ncbi The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer: results of a phase I study with pharmacokinetics
    Ahmad Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Eur J Cancer 44:84-91. 2008
    ..To investigate the safety and pharmacokinetics (PK) of combined treatment with letrozole and the oral mTOR inhibitor RAD001 in patients with metastatic breast cancer stable or progressing after > or = 4 months on letrozole alone...
  22. doi Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy
    Ahmad Awada
    Institut Jules Bordet, Medical Oncology Clinic, Brussels, Belgium
    Cancer Chemother Pharmacol 63:417-25. 2009
    ....
  23. pmc Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study
    A Awada
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Br J Cancer 98:1500-7. 2008
    ..Bortezomib plus docetaxel is an active combination for anthracycline-pretreated advanced/metastatic breast cancer. The safety profile is manageable and consistent with the side effects of the individual agents...
  24. doi AACR-NCI-EORTC International Conference 2009
    Ahmad Awada
    Jules Bordet Institute, Boulevard de Waterloo 121, Brussels, Belgium
    Expert Rev Anticancer Ther 10:319-20. 2010
    ..In this report, we will summarize the main topics discussed at this conference...
  25. doi Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial
    Ahmad Awada
    Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Pharmacol 51:1674-84. 2011
    ..Based on the overall toxicity profile and pharmacokinetic parameters, the recommended phase 2 doses were therefore sorafenib 400 mg bid and capecitabine 850 mg/m(2) bid, as scheduled above...
  26. doi Lapatinib ditosylate: expanding therapeutic options for receptor tyrosine-protein kinase erbB-2-positive breast cancer
    A Awada
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Drugs Today (Barc) 47:335-45. 2011
    ..Several clinical trials are still ongoing and data that may change current clinical practice are awaited with much interest...
  27. doi Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma
    Daniela D Rosa
    Department of Medicine, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Arch Gynecol Obstet 278:457-62. 2008
    ..We present data from heavily pretreated patients to whom the folinic acid, 5-fluorouracil and oxaliplatin (Folfox) regimen was administered. The objectives were to assess response rate and to evaluate the safety profile...
  28. doi EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma
    Yassine Lalami
    Institut Jules Bordet, Brussels, Belgium
    Radiother Oncol 105:238-40. 2012
    ....
  29. ncbi Review: side effects of approved molecular targeted therapies in solid cancers
    Christian Widakowich
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Oncologist 12:1443-55. 2007
    ....
  30. doi Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends
    Otto Metzger-Filho
    Institut Jules Bordet, Brussels, Belgium
    Expert Opin Investig Drugs 19:S31-9. 2010
    ..Better understanding of HER2 functions and interactions of different signalling pathways will be essential for optimal targetted therapies...
  31. doi Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
    Yassine Lalami
    Department of Medical Oncology, Institut Jules Bordet, université de Bruxelles, Brussels, Belgium
    Head Neck 38:347-54. 2016
    ..The purpose of this study was to assess the efficacy and safety of sorafenib in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) and to explore the predictive value of early metabolic responses...
  32. doi Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors
    Lissandra Dal Lago
    Head of the Medical Oncology Clinic, Jules Bordet Institute, Boulevard de Waterloo 121, B 1000 Brussels, Belgium
    Oncologist 13:845-58. 2008
    ..The primary objective of this review is to summarize the early clinical studies of sorafenib with cytotoxic agents and discuss future perspectives of these combinations in different tumor types...
  33. ncbi Salivary gland carcinomas, paranasal sinus cancers and melanoma of the head and neck: an update about rare but challenging tumors
    Yassine Lalami
    Jules Bordet Institute, Department of Internal Medicine, Medical Oncology Clinic, Brussels, Belgium
    Curr Opin Oncol 18:258-65. 2006
    ..This is a review about recent clinical developments in rare cancers of the head and neck...
  34. ncbi The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck
    Ahmad Awada
    Medical Oncology Department, Jules Bordet Institute, Brussels, Belgium
    Curr Opin Oncol 19:177-9. 2007
    ....
  35. ncbi Clinical trial design limitations in head and neck squamous cell carcinomas
    Hwan Jung Yun
    EORTC Data Center, Brussels, Belgium
    Curr Opin Oncol 19:210-5. 2007
    ..It provides critical analysis of their methodology in order to facilitate future trial design...
  36. ncbi Molecular targeted therapies in breast cancer: where are we now?
    Christian Widakowich
    Medical Oncology Clinic, Jules Bordet Institute, Rue Heger Bordet 1, 1000 Brussels, Belgium
    Int J Biochem Cell Biol 39:1375-87. 2007
    ..This paper will review the increasing role of molecular targeted therapies in BC, with a particular focus on those drugs currently being tested in early BC, as well as, on future perspectives...
  37. ncbi HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
    Christian Widakowich
    Medical Oncology Clinic, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium
    Anticancer Agents Med Chem 8:488-96. 2008
    ....
  38. doi Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib
    Mohammad Krayem
    Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Eur J Cancer 50:1310-20. 2014
    ..In conclusion, we report that (WT)BRAF/(WT)NRAS melanoma lines with low phospho-CRAF and high cAMP levels may be sensitive to vemurafenib and that CRAF inhibition through cAMP stimulation may overcome the resistance to the drug. ..
  39. doi Prevention and management of major side effects of targeted agents in breast cancer
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium
    Crit Rev Oncol Hematol 84:e79-85. 2012
    ..We critically analyse the available evidence and provide some insights on how to manage these toxicities in the clinical setting...
  40. doi Is tailored adjuvant treatment for colon cancer possible?
    Marc Van den Eynde
    Department of Medicine, Institut Jules Bordet, Universite Libre de Bruxelles, Belgium
    Clin Colorectal Cancer 9:15-21. 2010
    ..Herein, we review and discuss recent data about the most promising clinicopathologic and molecular factors described thus far and that are of interest in the management of patients with colon cancer...
  41. ncbi Does clinical and radiological response predict complete tumor control in N2-N3 squamous cell head and neck cancer after non-operative management of the neck?
    Didier Dequanter
    Department of Surgery, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Acta Otolaryngol 126:1225-8. 2006
    ..Consequently, early neck dissection should be advised for patients with complete clinical and radiological response (CCRR) after chemoradiotherapy for tumors with N2-N3 disease...
  42. ncbi Novel treatment strategies for malignant melanoma: a new beginning?
    Bernd Kasper
    Clinic of Medical Oncology, Institut Jules Bordet, Boulevard de Waterloo 125, Brussels 1000, Belgium
    Crit Rev Oncol Hematol 62:16-22. 2007
    ....
  43. ncbi Novel cytotoxic drugs: old challenges, new solutions
    Gustavo F V Ismael
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, Belgium
    Cancer Treat Rev 34:81-91. 2008
    ..In this review we highlight the development of promising novel cytotoxic drugs that will hopefully offer not only gains in efficacy, but also in safety, tolerability and convenience in the treatment of patients with cancer...
  44. ncbi Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives
    Otto Metzger-Filho
    Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
    Curr Clin Pharmacol 5:166-77. 2010
    ..Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on KRAS status are discussed...
  45. ncbi EORTC 10968: a phase I clinical and pharmacokinetic study of polyethylene glycol liposomal doxorubicin (Caelyx, Doxil) at a 6-week interval in patients with metastatic breast cancer. European Organization for Research and Treatment of Cancer
    A Hamilton
    IDBBC, Brussels, Belgium
    Ann Oncol 13:910-8. 2002
    ....
  46. doi Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
    Gil Awada
    a Internal Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium
    Expert Opin Emerg Drugs 21:91-101. 2016
    ..It is associated with more aggressive disease and worse clinical outcome. New drugs are thus needed. Approved and future treatments will be discussed in this review...
  47. ncbi Molecular-targeted therapies: lessons from years of clinical development
    Daniela D Rosa
    Medical Oncology Clinic, Jules Bordet Institute, and L Universite Libre de Bruxelles ULB, Brussels, Belgium
    Cancer Treat Rev 34:61-80. 2008
    ....
  48. doi Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients
    Pierre Vereecken
    Department of Dermatology, CHU Brugmann, Erasme Hospital, Brussels, Belgium
    Melanoma Res 19:316-20. 2009
    ..Further studies will uncover whether Gal-3 will be able to open new therapeutic perspectives...
  49. doi Management of head and neck cancer in elderly patients
    Yassine Lalami
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Drugs Aging 26:571-83. 2009
    ..In conclusion, once all physiological and biological risk factors have been addressed, a large proportion of geriatric patients can and should be offered the same HNC treatment as is offered to younger patients...
  50. doi Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
    Hampig Raphael Kourie
    a Medical Oncology Clinic, Jules Bordet Institute, Free University of Brussels, Brussels, Belgium
    Expert Opin Drug Metab Toxicol 12:947-57. 2016
    ..Neratinib is an irreversible pan-HER tyrosine kinase inhibitor in late-phase clinical development...
  51. doi Results of the Belgian expanded access program of eribulin in the treatment of metastatic breast cancer closely mirror those of the pivotal phase III trial
    Philippe Aftimos
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Belgium Electronic address
    Eur J Cancer 60:117-24. 2016
    ..Eribulin is a non-taxane microtubule dynamics inhibitor that showed a survival benefit versus treatment of physician's choice in a phase III trial enrolling patients with metastatic breast cancer (MBC)...
  52. pmc Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer
    Michail Ignatiadis
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 11:e0154009. 2016
    ..EndoTAG-1, a tumor endothelial targeting agent has shown activity in metastatic triple-negative breast cancer (BC) in combination with paclitaxel...
  53. doi p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib
    Mohammad Krayem
    Laboratory of Oncology and Experimental Surgery, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Eur J Cancer 55:98-110. 2016
    ..We conclude that PRIMA-1(Met) through its ability to directly reactivate p53 regardless of the mechanism causing its deactivation, and thereby dampen PI3K signalling, sensitises (V600E/K)BRAF-positive melanoma to BRAF inhibitors...
  54. doi Clinical development of new formulations of cytotoxics in solid tumors
    Hatem A Azim
    Breast Cancer Translational Research Laboratory BCTL J C Heuson, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 24:325-31. 2012
    ..To discuss the clinical development of new formulations of old cytotoxic agents and highlight the value of adopting this strategy...
  55. doi Survival benefit of eribulin mesylate in heavily pretreated metastatic breast cancer: what next?
    Philippe Aftimos
    Medical Oncology Clinic, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Adv Ther 28:973-85. 2011
    ..Future strategies of eribulin are being tested in ongoing trials, evaluating this drug in earlier metastatic lines as well as in the adjuvant and the neoadjuvant settings...
  56. ncbi Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions
    Chantal Bernard-Marty
    Jules Bordet Institute, Brussels, Belgium
    Drugs 66:1577-91. 2006
    ..Bevacizumab, a monoclonal antibody directed against vascular endothelial growth factor-A, is being evaluated in the metastatic setting for its antiangiogenic properties, and is showing promising results...
  57. ncbi Influence of amifostine on the toxicity and pharmacokinetics of docetaxel in metastatic breast cancer patients: a pilot study
    Gilles Freyer
    Laboratoire d Oncopharmacologie, Unite de Chimiotherapie, Service de Médecine Interne et Laboratoire d Investigation Clinique et d Oncologie Expérimentale HJ Tagnon, Institut Jules Bordet, 1000, Brussels, Belgium
    Clin Cancer Res 8:95-102. 2002
    ..For the other toxicities, which are usually cumulative, the present study has design limitations and further comparative trials are warranted...
  58. ncbi Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm)
    Gilberto de Castro Junior
    Medical Oncology Clinic, Institut Jules Bordet, Brussels, Belgium
    Crit Rev Oncol Hematol 59:40-50. 2006
    ..This review describes the mechanisms of the angiogenic process and evaluates the recent data about antiangiogenic therapies in clinical trials...
  59. ncbi Imatinib mesylate in a patient with metastatic disease originating from a dermatofibrosarcoma protuberans of the scalp
    Bernd Kasper
    Clinic of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    Anticancer Drugs 17:1223-5. 2006
    ..Our patient is now in sustained remission with minimal toxicity. We conclude that antitumor activity of metastatic dermatofibrosarcoma protuberans can be obtained with imatinib mesylate treatment with minimal side-effects...
  60. ncbi Novel treatment strategies for soft tissue sarcoma
    Bernd Kasper
    Clinic of Medical Oncology, Institut Jules Bordet, boulevard de Waterloo, 125, Brussels 1000, Belgium
    Crit Rev Oncol Hematol 62:9-15. 2007
    ....
  61. doi Recurrent thyroid cancer: a molecular-based therapeutic breakthrough
    Yassine Lalami
    Institut Jules Bordet, Medical Oncolgy Clinic, Universite Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 23:235-40. 2011
    ..Management of recurrent thyroid cancer not amenable to local therapy such as surgery, radiotherapy or radio-iodine ablation remains very challenging. Indeed, chemotherapy allows a very limited impact on the outcomes of this cancer...
  62. doi Sequential use of protein kinase inhibitors potentiates their toxicity to melanoma cells: a rationale to combine targeted drugs based on protein expression inhibition profiles
    Philippe G Aftimos
    Medical Oncology Clinic, Free University of Brussels, 1000 Brussels, Belgium
    Int J Oncol 43:919-26. 2013
    ....
  63. doi Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP)
    Felipe Ades
    Medical Oncology Clinic, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Brussels, Belgium
    J Chemother 25:239-46. 2013
    ..We concluded that in patients with newly diagnosed metastatic tumours, CupPrint has low accuracy in diagnosing the primary cancer site. ..
  64. ncbi New cytotoxic agents and molecular-targeted therapies in the treatment of metastatic breast cancer
    Ahmad Awada
    Clinique Adjoint, Medical Oncology, Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
    Forum (Genova) 12:4-15. 2002
    ..The growing availability of such biological therapies given alone and mainly in combination with hormonal and chemotherapeutic agents may improve in the near future the outcome of patients with metastatic breast cancer...
  65. ncbi A therapeutic approach to perianal extramammary Paget's disease: topical imiquimod can be useful to prevent or defer surgery
    Pierre Vereecken
    Departments of Dermatology, CHU Brugmann Hospital, Brussels, Belgium
    Med Sci Monit 13:CS75-7. 2007
    ..At clinical examination, lesions are well-defined eczematous areas and have been described typically in the anogenital region. Surgery is the cornerstone treatment...
  66. doi New therapies for ovarian cancer: cytotoxics and molecularly targeted agents
    Phuong Dinh
    Institut Jules Bordet, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 67:103-12. 2008
    ..It will also discuss other potential signal transduction targets worthy of further evaluation in future trials...
  67. doi Changing the clinical picture of challenging tumors: tales becoming reality?
    Camilo Moulin
    Jules Bordet Institute, 121 Bd de Waterloo, 1000 Brussels, Belgium
    Future Oncol 5:785-802. 2009
    ..This article aims to evaluate new insights and potential gains obtained with new therapies in a particular group of tumors: those rarely debated in clinical practice, but which still pose a considerable challenge to clinical oncology...
  68. doi [HER2 and topoisomerase II alpha: useful clinical markers in breast cancer]
    Denis Larsimont
    Département d Anatomie Pathologique, Institut Jules Bordet, 1000 Bruxelles, Belgique
    Bull Cancer 95:344-51. 2008
    ..More studies are needed today to consider this marker for daily practice...
  69. doi [Supportive care in cancer: concepts, achievements and challenges]
    Fanny Bauvet
    Service de Medecine, Clinique d oncologie médicale, Institut Jules Bordet, Universite Libre de Bruxelles ULB, Rue Heger Bordet 1, 1000 Bruxelles
    Bull Cancer 95:381-8. 2008
    ..It is necessary to know these side effects and their management in order to provide the best quality of care to the patients who receive these treatments...
  70. pmc Phase I study of Carzelesin (U-80,244) given (4-weekly) by intravenous bolus schedule
    A Awada
    Institut Jules Bordet, Brussels, Belgium
    Br J Cancer 79:1454-61. 1999
    ..There was no relationship between neutropenia and the AUC of the prodrug Carzelesin, but the presence of detectable plasma levels of the active metabolite U-76,074 was usually associated with a substantial decrease in ANC values...
  71. ncbi Carcinomatous meningitis as a clinical manifestation of pancreatic carcinoma
    A F Ferreira Filho
    Chemotherapy Unit, Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 12:1757-9. 2001
    ..To our knowledge, this is only the second case of carcinomatous meningitis secondary to a pancreatic carcinoma described so far...
  72. ncbi The feasibility of classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF) for pre- and post-menopausal node-positive breast cancer patients in a Belgian multicentric trial: a study of consistency in relative dose intensity (RDI) and cumulative dos
    A F Ferreira Filho
    Jules Bordet Institute, Brussels, Belgium
    Ann Oncol 13:416-21. 2002
    ..Concern has been raised regarding the feasibility of this regimen, especially in postmenopausal patients...
  73. ncbi Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours
    A Awada
    Chemotherapy Unit, Institut Jules Bordet, 1000, Brussels, Belgium
    Eur J Cancer 38:2272-8. 2002
    ..SCH 66336 can be safely administered using a continuous oral OD dosing regimen. The recommended dose for phase II studies using this regimen is 300 mg OD...
  74. ncbi Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy
    M J Piccart
    Jules Bordet Institute, Brussels, Belgium
    Int J Gynecol Cancer 13:196-203. 2003
    ..89 (0.59-1.33) and 0.82 (0.52-1.29). These results are suggestive of a treatment benefit but do not support a change in clinical practice. Other randomized clinical trials of intraperitoneal CT are reviewed and briefly discussed...
  75. ncbi Molecular profiling of head and neck tumors
    C Sotiriou
    Translational Unit, Jules Bordet Institute, Brussels, Belgium
    Curr Opin Oncol 16:211-4. 2004
    ..This article reviews recently reported studies that have used such approaches...
  76. ncbi Long-term survival in pituitary metastasis from breast cancer
    E Azambuja
    Institut Jules Bordet Centre de Tumeurs de l ULB, boulevard de Waterloo, 125, 1000 Brussels, Belgium
    Breast 15:446-7. 2006
    ..This patient was treated with surgery and radiotherapy in 1995 and during her second relapse, which occurred in 2004, chemotherapy was given. This treatment resulted in a partial response...
  77. pmc Correlating tumor metabolic progression index measured by serial FDG PET-CT, apparent diffusion coefficient measured by magnetic resonance imaging (MRI) and blood genomics to patient's outcome in advanced colorectal cancer: the CORIOLAN study
    Amélie Deleporte
    Medicine Department, Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    BMC Cancer 14:385. 2014
    ..There is presently no available tool designed to assess tumor aggressiveness, despite the fact that this is considered to have a major impact on patient outcome...
  78. doi Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC)
    Jean Klastersky
    Department of Medicine, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, 121 Boulevard de Waterloo, 1000 Bruxelles, Belgium
    Crit Rev Oncol Hematol 81:49-57. 2012
    ..It is likely that other biologically targeted therapies will be developed in a near future. These progresses will lead hopefully to a more personalized and effective treatment of NSCLC...
  79. ncbi Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation
    Phillipe Lothaire
    Department of Surgery, Institut Jules Bordet, Brussels, Belgium
    Head Neck 28:256-69. 2006
    ..The aim of this article is to review recent developments in the biological understanding of head and neck squamous cell carcinomas...
  80. doi Treatment of recurrent thyroid cancers--is there a light in the horizon?
    Rodrigo Kraft Rovere
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Curr Opin Oncol 20:245-8. 2008
    ..The reported response rates of recurrent thyroid cancer to chemotherapy are generally poor. Molecular studies have provided some information on their biology and have identified new targets with therapeutic potential...
  81. doi Prevention of febrile neutropenia in chemotherapy-treated cancer patients: Pegylated versus standard myeloid colony stimulating factors. Do we have a choice?
    Jean Klastersky
    Department of Medicine, Jules Bordet Institute, Centre des Tumeurs de l Universite Libre de Bruxelles, Belgium
    Crit Rev Oncol Hematol 78:17-23. 2011
    ....
  82. doi Febrile neutropenia: a critical review of the initial management
    Jean Klastersky
    Department of Medicine, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Brussels, Belgium
    Crit Rev Oncol Hematol 78:185-94. 2011
    ..While the algorithm for therapy in low-risk patients is presently straightforward, significant progresses are needed for patients who are at higher risk of presenting severe complications...
  83. ncbi Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer
    M J Piccart
    Jules Bordet Institute, Chemotherapy Unit, Brussels, Belgium
    J Clin Oncol 15:3149-55. 1997
    ....
  84. doi Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives
    Yousra Akasbi
    Hassan II University Hospital, Medical Oncology Department, Morocco
    Bull Cancer 99:92-9. 2012
    ..In addition, this review will focus on the recent understanding of carcinogenesis and consequently highlight potential "targeted" therapeutic interventions...
  85. ncbi Concomitant chemo-radiotherapy as standard therapy in limited-stage small-cell oesophageal cancer: a summary of 3 clinical cases and review of the literature
    Bertrand Vos
    Gastroenterology Department, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium
    Acta Gastroenterol Belg 71:325-9. 2008
    ..Chemo-radiotherapy should be considered as a valuable treatment alternative to surgery for limited-stage small-cell carcinoma of the oesophagus...
  86. ncbi Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation
    M S Mano
    Unite de Chimiotherapie, Institut Jules Bordet, Boulevard de Waterloo 125, Brussels 1000, Belgium
    Breast 13:347-9. 2004
    ..Interestingly, there was no evidence of Ras-Raf-MAPK or PI3K-Akt pathways activation...
  87. ncbi Remaining controversies in the upfront management of advanced ovarian cancer
    M S Mano
    Unite de Chimiotherapie, Institut Jules Bordet, Brussels, Belgium
    Int J Gynecol Cancer 14:707-20. 2004
    ..In this article, we review the rationale behind these controversial issues, and provide the levels of evidence supporting the current recommendations for AOC management...
  88. ncbi An integrated approach for tailored treatment in breast cancer
    A Awada
    Institut Jules Bordet, Medical Oncology Clinic, Brussels, Belgium
    Ann Oncol 16:ii203-8. 2005
  89. ncbi Strategies offering protection from the toxic effects of anticancer treatments with a focus on chemoprotective agents
    A Awada
    Institut Jules Bordet, Brussels, Belgium
    Curr Opin Oncol 12:289-96. 2000
    ..Means or agents designed to alleviate toxicities of anticancer treatments have been marketed or are under active investigation. In this paper, we review the reports published in this field in 1999...
  90. ncbi Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer
    G Atalay
    Jules Bordet Institute, Department of Medical Oncology, Brussels, Belgium
    Ann Oncol 14:1346-63. 2003
    ..The aim of this review is to provide clinicians with an updated synopsis of the most advanced anti-erbB therapeutic strategies with activity against BC...
  91. ncbi Current management of ovarian carcinosarcoma
    M S Mano
    Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    Int J Gynecol Cancer 17:316-24. 2007
    ..However, this procedure has been associated with higher rates of complication in OCS and should only be attempted by experienced (gynecological) surgeons in centers with expertise in the management of gynecological malignancies...
  92. doi The use of low-energy laser (LEL) for the prevention of chemotherapy- and/or radiotherapy-induced oral mucositis in cancer patients: results from two prospective studies
    M T Genot-Klastersky
    Department of Medicine, Institut Jules Bordet, Centre des Tumeurs de l Universite Libre de Bruxelles, Rue Heger Bordet, 1, Brussels, 1000, Belgium
    Support Care Cancer 16:1381-7. 2008
    ..Low-energy laser (LEL) treatment has been suggested as an effective and safe method to prevent and/or treat oral mucositis induced by chemotherapy and/or radiotherapy; however, it has not gained wide acceptance so far...
  93. ncbi Expression of galectin-3 in primary and metastatic melanoma: immunohistochemical studies on human lesions and nude mice xenograft tumors
    Pierre Vereecken
    Department of Dermatology, Erasme University Hospital, 808 Lennikstreet, 1070, Brussels, Belgium
    Arch Dermatol Res 296:353-8. 2005
    ..We propose Gal-3 expression in melanoma as a diagnostic and/or a prognostic parameter and suggest that further studies of such a role for Gal-3 are warranted...
  94. ncbi Anticancer chemotherapy in a patient with prior history of acute intermittent porphyria. A case report and review of the literature
    F Forget
    Jules Bordet Institute, Chemotherapy Unit, Brussels, Belgium
    Support Care Cancer 9:465-6. 2001
    ..Hematin and supportive treatments were useful treatments in our patient...
  95. ncbi Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma
    M S Mano
    Unite de Chimiotherapie, Institut Jules Bordet, Brussels, Belgium
    Gynecol Oncol 92:887-95. 2004
    ..In this study, we investigated the actual rates of T2a and HER-2 amplification and overexpression by fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC), respectively...
  96. ncbi Management of cutaneous locoregional recurrences of melanoma: a new therapeutic perspective with imiquimod
    Pierre Vereecken
    Dermatology 206:279-80. 2003
  97. ncbi Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors
    Dirk Strumberg
    Department of Internal Medicine and Medical Oncology, West German Cancer Center, University Medical School of Essen, Germany
    J Clin Oncol 23:965-72. 2005
    ..This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors...
  98. ncbi Molecular markers, molecular-targeted therapies and taxanes: how to integrate the progress into clinical research and practice for the management of head and neck cancers
    Ahmad Awada
    Curr Opin Oncol 17:209-11. 2005
  99. ncbi Adjuvant anthracycline-based chemotherapy for early breast cancer: do the dose and schedule matter?
    Max S Mano
    Beatson Oncology Centre, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, Scotland, UK
    Cancer Treat Rev 31:69-78. 2005
    ..Unfortunately, as research is moving towards other more important questions, many of these uncertainties may never be clarified. In this paper, we review the current evidence behind some of the most commonly used anthracycline schedules...
  100. ncbi Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer
    Lillian L Siu
    Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada M5G 2M9
    Clin Cancer Res 12:144-51. 2006
    ..This study is designed to combine sorafenib and gemcitabine due to their compatibility in preclinical models and nonoverlapping clinical toxicities...
  101. ncbi Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Jean Bourhis
    Institut Gustave Roussy, Radiotherapie, Villejuif, France
    J Clin Oncol 24:2866-72. 2006
    ..This was an open, randomized, multicenter, phase I/II study to investigate the safety and tolerability of cetuximab in the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN)...